Geneva, Switzerland - January 25, 2017 - ObsEva SA (ObsEva) announced today the pricing of its initial
public offering of 6,450,000 common shares at the initial public offering price of $15.00 per share. In addition, ObsEva has
granted the underwriters an option to purchase up to 967,500 additional common shares to cover over-allotments. The offering
is expected to close on or about January 31, 2017, subject to customary closing conditions. ObsEva's common shares have been
approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol "OBSV" on January
26, 2017.
Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are acting as joint book-running
managers for the proposed offering.
A registration statement relating to the securities being sold in this offering was declared effective by the
Securities and Exchange Commission on January 25, 2017. This offering is being made only by means of a written prospectus
forming part of the effective registration statement. A copy of the final prospectus, when available, may be obtained for
free by visiting the SEC's website at www.sec.gov. Alternatively, copies of the preliminary prospectus and the final prospectus, when
available, may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New
York, NY 10010, by telephone at 1-800-221-1037, or by email at newyork.prospectus@credit-suisse.com; from Jefferies LLC, Attention: Prospectus Department, 520
Madison Avenue, 2nd Floor, New York, NY 10022, by emailing Prospectus_Department@Jefferies.com, or by calling 1-877-821-7388; or from Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by email at syndicate@leerink.com, or by calling 1-800-808-7525 ex. 6142.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ObsEva SA
ObsEva is a biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics from
conception to birth. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with
potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has
established a clinical-stage pipeline with multiple development programs focused on treating the symptoms associated with uterine
fibroids and endometriosis, improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization, and
treating preterm labor.
MEDIA CONTACT
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526
COMPANY CONTACT
Delphine Renaud
ObsEva, CEO Office
delphine.renaud@obseva.ch
+41 22 552 1550
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/a277f942-f8af-486b-ae93-8fd52c0082c0
